Phio Pharmaceuticals Corp. 8-K Summary
Business Context and Reporting Period
This Form 8-K Current Report, dated February 4, 2020, details a material definitive agreement entered into by Phio Pharmaceuticals Corp. The transaction closed on February 6, 2020. The company is incorporated in Delaware and trades on The Nasdaq Capital Market under the symbol PHIO.
Key Financial Metrics
The filing reports a capital raise through a registered offering and a concurrent private placement. Key financial figures include:
- Common Stock Sold: 197,056 shares at $8.705 per share.
- Warrants Issued: Warrants exercisable for 197,056 shares (100% of shares sold) at an exercise price of $8.71 per share.
- Net Proceeds: Approximately $1.4 million after deducting fees and expenses.
- Placement Agent Fees: 7.5% cash fee, 1.0% management fee, plus $40,000 for non-accountable expenses, $50,000 for legal expenses, and $12,900 for clearing fees.
- Placement Agent Warrants: 14,779 warrants issued to the agent (7.5% of shares sold) with an exercise price of $11.0375 per share.
The filing text does not provide clear values for revenue, profit, cash flow, margins, or existing debt levels, as this report focuses solely on the equity transaction.
Material Changes
The primary material change is the increase in equity capital and the issuance of new warrants. The company raised approximately $1.4 million in net proceeds. This transaction increases the number of outstanding shares and warrants, potentially diluting existing shareholders upon exercise.
Outlook, Risks, and Contingencies
Management Commentary: The company utilized a shelf registration statement (Form S-3) for the common stock portion of the offering. The warrants and warrant shares were sold unregistered under Section 4(a)(2) and Rule 506 exemptions.
Risks and Terms:
- Warrant Expiration: Investor warrants expire 5.5 years from issuance; Placement Agent Warrants expire on February 4, 2025.
- Ownership Limitations: Warrants are subject to certain ownership limitations.
- Registration Status: The warrants and shares issuable thereunder are not registered under the Securities Act of 1933.
Investor Verification Checklist
- Verify the exact number of shares outstanding post-closing to assess dilution impact.
- Confirm the company's current cash position and burn rate to determine runway extension from the $1.4 million net proceeds.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants or restrictions.
- Check subsequent filings for the actual closing date confirmation and final share count.